Novel antimicrobials targeting MDR pathogens from animal microbial symbionts

针对动物微生物共生体中的耐多药病原体的新型抗菌药物

基本信息

批准号：
10592380
负责人：
David R Andes
金额：
$ 595.5万
依托单位：
UNIVERSITY OF WISCONSIN-MADISON
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-04-01 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10592380
关键词：
Address Anabolism Animals Anti-Infective Agents Antibiotics Antimicrobial Resistance Bacteria Biological Biological Assay Chemicals Computational Biology Culture Techniques Development Drug resistance Ecology Environment Epidemic Genomics Goals Health Human In Vitro Invertebrates Investigation Lead Libraries Medicine Methods Microbe Microbial Genome Sequencing Mining Minority Natural Compound Natural Products Natural Products Chemistry Pathogenesis Pathway interactions Pharmaceutical Preparations Production Property Public Health Research Resistance Resources Safety Series Soil Source Streptomyces Symbiosis Taxon Techniques Technology Testing Therapeutic Wisconsin Work antimicrobial antimicrobial drug antimicrobial resistant infection clinical development combat drug development drug discovery drug resistant bacteria drug resistant pathogen effective therapy fungus in vivo industry partner innovation insight marine metabolomics microbial microbiome multi-drug resistant pathogen multidisciplinary natural antimicrobial next generation novel novel therapeutics pathogen pathogenic bacteria pathogenic fungus pre-clinical preclinical study scaffold secondary metabolite small molecule success symbiont theories

项目摘要

Project Summary The discovery of new antimicrobials has failed to keep pace with the emergence of antimicrobial-resistant infections, threatening public health. The overarching goal of the Wisconsin Antimicrobial Drug Discovery and Development Center is to develop therapeutic countermeasures to tackle the antimicrobial resistance crisis. Based upon our preliminary investigations using interdisciplinary, cutting-edge approaches, we hypothesize that natural products from animal-microbe symbioses represent a new paradigm in antimicrobial drug discovery. The Center proposes innovative conceptual and technical advances to overcome the critical bottlenecks of traditional antimicrobial discovery to deliver therapeutic countermeasures for the drug-resistance epidemic. Relevance There is an ever-present and growing need to find novel, effective therapies for emerging resistant pathogens that are becoming an increasing threat to the public health. The goals of the Center are to discover new antimicrobial drugs. Our collaborative effort focuses on high-value natural products produced by under- explored sources of biological and chemical diversity.

项目摘要新抗菌剂的发现未能跟上抗菌抗菌的出现感染，威胁公共卫生。威斯康星州抗菌药物发现的总体目标开发中心将开发治疗性对策，以应对抗菌抗性危机。根据我们使用跨学科的尖端方法进行初步调查，我们假设来自动物 - 微生物共生的天然产物代表了抗菌药物发现的新范式。这中心提出了创新的概念和技术进步，以克服传统的关键瓶颈抗菌剂发现以提供抗药性流行的治疗对策。关联寻找新颖的，有效的抗性病原体的新颖有效疗法的需求越来越不断增长对公共卫生的威胁越来越大。该中心的目标是发现新的抗菌药物。我们的协作努力着重于低价值天然产品探索了生物学和化学多样性的来源。